NKTR Nektar Therapeutics Inc Total Asset Value of Company
Nektar Therapeutics (NKTR) specializes in developing treatments for oncology and autoimmune pathologies, targeting the global biotech market through molecular modification. This chart of the price dynamics for total assets, valued at 651.45, confirms the scale of operations. The business model enables the global scaling of proprietary developments with high margins. However, the company currently lacks pricing power, relying on grants and remaining funds following a strategic pivot.
Analytical breakdowns and data insights for company Nektar (NKTR)
- stock price and consensus target price:
- market capitalization data:
- issuer book value statistics:
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Nektar Therapeutics|NKTR - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Nektar Corp|NKTR - Company Aggregate Debts|Debts to Book Capitalization Nektar Corp|NKTR - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Nektar Therapeutics|Interim Coverage Ratio nektar.com
- net income and valuation multiples indicators:
Fundamental valuation:Nektar Therapeutics
The success of Nektar Therapeutics (NKTR) depends on the effective capitalization of intellectual property and licensing agreements for immunotherapeutic drugs. By analyzing the magnitude of consolidated assets calculated reverse-engineered through ROA, an investor assesses the company's actual resource volume relative to industry standards. This metric reveals systemic business degradation, allowing one to distinguish a temporary drawdown from an irreversible loss of the fundamental base and capital management inefficiency.
Key competitors
argenx.com - Aggregate Asset Value|Aggregate Company Assets BioNTech|Abivax - Total Asset Value of Company|Company Total Assets ADMA|PTGX (Protagonist Corp) - Aggregate Asset Value|Company Total Assets IMVT (Immunovant, Inc.)|Company Total Assets kiniksa.com KNSA|GRFS - Aggregate Company Assets|Aggregate Asset Value ADPT (Adaptive Biotech)|Celldex (CLDX) - Aggregate Company Assets|Cumulative Company Assets Aurinia Corp|BCRX (BioCryst) - Company Total Assets|Company Total Assets veratx.com|Cumulative Company Assets DNTH (Dianthus Therapeutics, Inc.)|PHVS (Pharvaris NV) - Aggregate Asset Value|Company Total Assets ABCL (abcellera.com)|Company Total Asset Base Tourmaline (TRML)|PGEN - Aggregate Company Assets|pharming.com (PHAR) - Cumulative Company Assets|Upstream Bio (UPB) - Aggregate Company Assets|Cumulative Company Assets Zenas Bio|Cumulative Company Assets IMNM|Company Total Assets Gossamer Bio Corp.|Aggregate Company Assets KalVista Pharmaceuticals (KALV)|septerna.com - Total Business Assets|Company Total Assets PVLA (Pieris Pharmaceuticals, Inc.)|Savara Inc (SVRA) - Company Assets|RIGL - Aggregate Company Assets|ANAB (AnaptysBio Inc.) - Total Business Assets|ATXS: Company Total Assets|Company Assets engene.com (ENGN)|Aggregate Company Assets RAPT Therapeutics|Company Total Assets Aerovate|Cumulative Company Assets ACRS (Aclaris)|Aggregate Business Assets KYTX|Company Total Assets TLSA (Tiziana Life Sciences)|Company Total Assets cabalettabio.com CABA|VTYX - Aggregate Company Assets|Aggregate Asset Value THTX (Theratechnologies, Inc.)|AVTX (Avalo Therapeutics Inc.) - Cumulative Company Assets|Eledon Pharmaceuticals, Inc - Aggregate Asset Value|Cumulative Company Assets AGEN|CLYM (climbbio.com) - Aggregate Business Assets|Company Total Assets ZURA|ATYR (aTyr Pharma Inc) - Aggregate Asset Value|Company Total Assets ADAG (Adagene Inc.)|ImageneBio (IMA) - Company Assets|STTK - Aggregate Company Assets|Aggregate Asset Value EQ (Equillium, Inc.)|CNTB: Company Total Assets|Immunic (IMUX) - Company Total Assets|Aggregate Company Assets Atara Biotherapeutics, Inc.|InflaRx GmbH - Total Asset Value of Company|Company Total Assets XFOR|ACET - Company Assets|Celularity - Cumulative Company Assets|Company Total Assets INmune Bio Inc INMB|BRNS: Cumulative Company Assets|Kezar Life Sciences Inc - Aggregate Business Assets|SABS: Company Total Assets|AKTX - Company Total Asset Base|ENLV (Enlivex Therapeutics Ltd) - Company Total Assets|Cumulative Company Assets Q32 Bio Corp (QTTB)|Aggregate Company Assets GeoVax Labs Inc (GOVX)|Company Total Asset Base Edesa Biotech Corp|Aggregate Company Assets iBio, Inc. IBIO|CARM: Total Business Assets|XTLB - Aggregate Company Assets|BOLT - Company Total Assets|HCWB (hcwbiologics.com) - Cumulative Company Assets|APVO: Aggregate Business Assets|Aggregate Company Assets AIM ImmunoTech Inc.|ADTX: Aggregate Asset Value|Aggregate Company Assets GRI Bio (GRI)|XRTX: Total Asset Value of Company|Company Total Assets HIND (ReShape Lifesciences)|Aggregate Asset Value REVB|Indaptus Therapeutics - Company Total Assets|SCNI - Company Total Assets|calcimedica.com (CALI) - Aggregate Company Assets|Affimed N.V. - Aggregate Asset Value|Aggregate Company Assets Allakos Inc|Cumulative Company Assets HOOKIPA (HOOK)|Company Total Assets IGMS|Company Total Assets iteostherapeutics.com (ITOS)|Ocean Biomedical - Cumulative Company Assets|Aggregate Asset Value TCBP|Third Harmonic Bio, Inc - Company Total Assets